ArticleBMC microbiology2025
Genetic diversity and antifungal resistance in Candida albicans from VVC cases in Indian women.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Natural product based approaches to overcomeFrontiers in antibiotics · 2026Review
- OvercomingFrontiers in antibiotics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVulvovaginal candidiasis (VVC) is a common fungal infection primarily caused by Candida albicans. It is associated with significant morbidity, especially in recurrent cases. Antifungal resistance, particularly to azole drugs, poses a growing challenge in treatment.
aimThis study investigates the genetic diversity and antifungal resistance patterns of C. albicans isolated from VVC patients.
methodA total of 170 vaginal swab samples were collected from Indian women attending the obstetrics and gynecology departments at IMS SUM Hospital and Kalinga Hospital, Odisha, India. C. albicans isolates were identified through microscopic analysis, growth on HiCrome™ Candida Differential Agar, germ tube formation tests, and the Vitek2 Compact system. Antifungal susceptibility was determined using the Kirby-Bauer disk diffusion method. Genetic diversity was assessed through Inter-Simple Sequence Repeat (ISSR) and Random Amplified Polymorphic DNA (RAPD) marker techniques. The data were analyzed using dendrograms, genetic similarity matrices, and Principal Component Analysis (PCA).
resultsOut of 170 vaginal swabs, 122 Candida isolates were identified, with 35 confirmed as C. albicans. Eighteen representative C. albicans isolates were analyzed for genetic diversity. Antifungal susceptibility tests revealed that Nystatin showed the highest sensitivity (60%), followed by miconazole (54.29%) and fluconazole (42.86%). In contrast, ketoconazole and voriconazole exhibited the highest resistance rates (60%). Itraconazole and clotrimazole also showed considerable resistance at 51.43% and 48.57%, respectively. Amphotericin B demonstrated moderate efficacy, with 20% sensitivity and a high intermediate response (45.71%). Genetic diversity analysis using ISSR and RAPD markers showed considerable polymorphism, indicating a heterogeneous C. albicans population. Strain S95 exhibited significant genetic divergence compared to other isolates, suggesting unique genetic characteristics. Both dendrograms and PCA identified distinct genetic clusters within the isolates.
conclusionThe study demonstrates significant genetic variability among C. albicans isolates and widespread antifungal resistance, particularly to azole-based treatments. The results underscore the importance of regular monitoring of genetic diversity and resistance patterns in C. albicans to guide effective treatment strategies for VVC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.